Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Development and Validation of a New RP-HPLC Method for the Determination of Aprepitant in Solid Dosage Forms

Sreekanth Nama¹ , Babu R Chandu², Bahlul Z Awen², Mukkanti Khagga³

¹Department of Pharmacy, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia; ²Al-Jabal Al-Gharbi University, Al-Zawia, Libya; ³Centre for Chemical Sciences and Technology, IST, J.N.T.University, Kukatpally, Hyderabad, Andhrapradesh - 500 085, India.

For correspondence:- Sreekanth Nama Email: sreekanthpharma@yahoo.co.in Tel:+251917498574

Received: 29 November 2010 Accepted: 27 June 2011 Published: 20 August 2011

Citation: Nama S, Chandu BR, Awen BZ, Khagga M. Development and Validation of a New RP-HPLC Method for the Determination of Aprepitant in Solid Dosage Forms. Trop J Pharm Res 2011; 10(4):491-497 doi: 10.4314/tjpr.v10i4.15

© 2011 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop and validate a new, simple, sensitive, rapid, cost-effective and accurate reverse phase-high performance liquid chromatography (RP-HPLC) method for the determination of aprepitant (APT) in capsule dosage form.

Methods: The method developed for the determination of APT in capsule formulation involved using RP-HPLC which incorporated a C₁₈column 250 x 2.5 mm i.d, 5 µm particle size, in isocratic mode, with mobile phase comprising of methanol: water in the ratio of 90:10 (v/v). The flow rate was 1 mL/min and the detection was monitored at 220 nm. The total run time was 10 min and the column was maintained at ambient temperature.

Results: APT was eluted in the given mobile phase with a retention time (t_r) of 4.473 min. The linearity for the quantification of APT was 0.1 - 10 µg/mL (R² =0.989, Y= 33032x + 71501) with coefficients of variation (based on mean peak area for six replicate injections) in the range 0.04 to 0.132. The limits of detection and of quantification were 0.028 and 0.094 µg/mL, respectively. Recovery of the method was 99.56 - 100.5 % while the relative standard deviation (RSD) of intra-day and inter-day precision was 0.85 and 1.05, respectively. System precision and method precision were 0.013 and 1.400 %, respectively. The specificity data of the proposed method indicated that excipients in the capsules did not interfere with the drug peak. Furthermore, the well-shaped peaks buttressed the specificity of the method.

Conclusion: The proposed RP-HPLC method is simple, sensitive, rapid, cost-effective and accurate for the determination of APT in both bulk materials and pharmaceutical dosage forms.

Keywords: Keywords: Aprepitant, RP-HPLC, Isocratic, Pharmaceutical dosage forms, Analysis, Validation